ArcheMedX Releases Largest Confidence-Based Assessment Dataset in CNS Clinical Research at CNS Summit 2025
ArcheMedX shares the largest CBA dataset in CNS trials, revealing hidden training risks and how to reduce them
Raising the Bar: Why Quality and Training Will Define Your Success Under ICH E6(R3)
The formal Formal adoption of the E6(R3) guideline introduces a proportionate and more modern risk-based approach to quality management. Clinical trial leaders must implement more effective training programs that address increased trial complexity and ensure compliance with the enhanced quality requirements.
ArcheMedX Celebrates Key Milestones for Ready Platform Since DIA Launch
Ready has powered more than 1,000,000 user sessions with clinical professionals from over 90 countries to become the preferred study training tool for over 80% of site personnel.
ArcheMedX Reports Exceptional Results of REMS Opioid Analgesic Programs for 54,000 Healthcare Providers
54,000 Healthcare Providers dramatically increased their knowledge and confidence in effectively diagnosing, treating, and managing patients with pain after completing more interactive medical education powered by ArcheMedX
ArcheMedX To Present New Findings & Clinical Trial Innovations At The CNS Summit
Analyses of 42,656 clinician learners across 69 CNS-related educational activities reveals clinicians may be unprepared to effectively conduct clinical trials
Charlottesville, VA (PRWeb) November 16, 2022
ArcheMedX, the leading provider of clinician readiness solutions for the life sciences and healthcare industries, today announced the Company’s expanded participation at the CNS Summit taking
ArcheMedX Releases New Oncology Findings Ahead Of ESMO Congress Revealing Clinician Readiness
2021 was a historic year in the battle to defeat cancer.
More novel cancer treatments became available than ever before with the number of Oncology specific clinical trials also reaching an all-time high, up 56% from 2016 and mostly focused on rare cancer indications.
With global spending on Oncology expected to exceed $300
ArcheMedX Achieves Data Milestone Modeling Over 25 Million Learning Behaviors
ArcheMedX, a behavioral science-based learning company providing a smarter way to predict and improve clinical team performance, recently passed a significant data milestone.
PRWeb - Charlottesville, VA March 24, 2022
Today, the Company announced its clinician learning and predictive analytics platform, Ready, has now surpassed more than 25 million essential learning behaviors
ArcheMedX Releases New Findings at CNS Summit Revealing Clinician Readiness
The area of clinical research known as CNS (central nervous system conditions) is commonly cited for its complexity and the subjective nature of many assessment tools. CNS clinicians therefore must commit to tackling unique challenges affecting their patients and the research they conduct.
It should be no surprise that the life
AMA Recognizes ArcheMedX’s COVID-19 Report on Virtual Tech in Clinical Trials for Excellence
Today, ArcheMedX announced that its 2020 industry report, “COVID-19's Impact on Virtual Tech in Clinical Trials, was honored with a prestigious American Marketing Association (AMA) award.
Every year, the AMA honors hundreds of stand-out marketers through awards programs presented by the AMA Foundation, local professional chapters, and academic special interest groups.
Webinar: Transforming Study Start Up to Reduce Clinical Trial Site Burden
Watch on Demand Now!
Clinical trials are more complex than ever.
And 85% of them are delayed.
More screening criteria, more procedures, new vendor systems and tools, and more data. So who bears the burden of all this progress? Sites.
Increased site burden means degraded performance, more delays, and more problems for you. But
